Blockchain Registration Transaction Record
Kairos Pharma Issues Shareholder Letter Outlining Progress and Strategic Developments
Kairos Pharma updates progress on ENV105 clinical trials for prostate and lung cancers, highlighting advancements in oncology therapeutics. CEO John Yu, M.D., shares strategic developments in a shareholder letter, underscoring the company's strong financial position and IP portfolio.
This news matters as it showcases Kairos Pharma's advancements in oncology therapeutics, particularly in overcoming drug resistance and immune suppression in cancer. The progress in ENV105 clinical trials for various cancer types signifies potential breakthroughs in addressing unmet medical needs, offering hope for improved treatment outcomes for patients.
| Blockchain | Details |
|---|---|
| Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
| Transaction ID | 0x0552b454aaa4a36d04f6711c3747c772627aa8221dd517f7511e3f52e6df04bd |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | calmc60_-11b56ea13aefbdbb4f9964a47b9b4772 |